Mr. Carter has been a director since May 2018 and is a member of Mallinckrodt’s Audit Committee.
He has been a director of Alder Biopharmaceuticals, Inc., since 2015, and Hutchison China MediTech Ltd. since 2017.
Mr. Carter served in various roles at Gilead Sciences, Inc. from April 2006 to August 2016, most recently serving as executive vice president, commercial operations. Prior to joining Gilead, Mr. Carter spent 15 years in the pharmaceutical industry with GlaxoSmithKline plc and its legacy companies where he held various roles with increasing levels of senior experience, including general manager in Europe and as a regional head of the international business in Asia. Mr. Carter also serves as a healthcare advisor to several biotechnology companies.
Mr. Carter is a fellow of the Chartered Institute of Management Accountants (FCMA), and holds a BA Honours degree in Business Studies from the University of West London in the U.K.